PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology 2016; 69: 177-186.Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K, et al. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology...
A-C: Comparison of CPS, TPS and IPS interpretation results using PD-L1 22C3, E1L3N XP, CST E1L3N, BP6099 and MXR006 antibodies in each case. D: Distribution and median comparison of CPS, TPS and IPS interpr...
Although PD-L1 IHC test is now deployed in most pathology laboratories, its appropriate implementation and interpretation are critical as a predictive biomarker and can be challenging owing to the multiple antibody clones and platforms or assays available and given the typically small size of samples ...
21. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint pd-l1 ihc assay comparison project. J Thorac Oncol. 2017;12(2):208-222. 22. Ye M, ...
2 Interpretation results of CPS (A) and TPS (B) at cut-off 1 and 10, respectively, using PD-L1 22C3, SP263 and 28-8 antibodies in ESCC The agreement between CPS and TPS was analyzed by Kappa test. 2.3 ESCC中PD-L1 22C3与4种国产抗体检测 的一致性分析 进行PD-L1 22C3与4...
12. Udall M, et al. Diagn Pathol. 2018; 13(1): 12. 13. PD-L1 IHC 28-8 pharmDx. Interpretation Manual, Non-Squamous Non-Small Cell Lung Cancer. 14. Cree IA, et al. Histopathology. 2016; 69(2): 177-186. NP/IO/4160/08/22/19-08/22/20...
3. Agilent Technologies, Inc. PD-L1 IHC 22C3 pharmDx Interpretation Manual – NSCLC 4. S. Gadgeel , et al. 1296O ESMO2017-Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2+L1NSCLC: Results from the randomized OAK study ...
15. Kalpakoff M, Hund S, Musser J, et al. Intrapatient tumor heterogeneity in IHC interpretation using PD-L1 IHC 22C3 pharmDx. Appl Immunohistochem Mol Morphol. 2021;29(9):667-673. 16. Liu D, Wang S, Bindeman W. Clinical applications of PD-L1 bioassays for cancer immunotherapy. J ...
p40/PD-L1 and TTF1/PD-L1 Immunohistochemical Double Staining Contributes to Intraindividual Variability Associated With PD-L1 Staining Interpretation in Lu... The important developments achieved in recent years with a consequent paradigm shift in the treatment of non-small cell lung cancer (NSCLC),...
11. Nivolumab Labels for BLA. 2019/02 12. Udall M, et al. Diagn Pathol. 2018; 13(1): 12. 13. PD-L1 IHC 28-8 pharmDx. Interpretation Manual, Non-Squamous Non-Small Cell Lung Cancer. 14. Cree IA, et al. Histopathology. 2016; 69(2): 177-186....